iScience



Article

An ATX-LPA₆-G α_{13} -ROCK axis shapes and maintains caudal vein plexus in zebrafish



Ryohei Okasato, Kuniyuki Kano, Ryoji Kise, Asuka Inoue, Shigetomo Fukuhara, Junken Aoki

jaoki@mol.f.u-tokyo.ac.jp

Highlights

Blocking an ATX-LPA₆-G α_{13} -ROCK axis causes malformation of the caudal vein plexus

The axis also contributes to maintaining the fine structure of the caudal vein plexus

Activation of LPA₆ induces vasoconstriction

Caudal vein plexus formation evoked by blood flow is dependent on an ATX-LPA₆ axis

Okasato et al., iScience 24, 103254 November 19, 2021 © 2021 The Authors. https://doi.org/10.1016/ j.isci.2021.103254



iScience

Article

An ATX-LPA₆-G α_{13} -ROCK axis shapes and maintains caudal vein plexus in zebrafish

Ryohei Okasato,^{1,2,3} Kuniyuki Kano,^{1,2,3} Ryoji Kise,² Asuka Inoue,^{2,3} Shigetomo Fukuhara,⁴ and Junken Aoki^{1,2,3,5,*}

SUMMARY

Lysophosphatidic acid (LPA) is a potential regulator of vascular formation derived from blood. In this study, we utilized zebrafish as a model organism to monitor the blood vessel formation in detail. Zebrafish mutant of ATX, an LPA-producing enzyme, had a defect in the caudal vein plexus (CVP). Pharmacological inhibition of ATX resulted in a fusion of the delicate vessels in the CVP to form large sac-like vessels. Mutant embryos of LPA₆ receptor and downstream $G\alpha_{13}$ showed the same phenotype. Administration of OMPT, a stable LPA-analog, induced rapid CVP constriction, which was attenuated significantly in the LPA₆ mutant. We also found that blood flow-induced CVP formation was dependent on ATX. The present study demonstrated that the ATX-LPA₆ axis acts cooperatively with blood flow and contributes to the formation and maintenance of the CVP by generating contractive force in endothelial cells.

INTRODUCTION

Vascular endothelial growth factor (VEGF, mainly VEGF-A) has received the most attention as the central molecule responsible for angiogenesis (Apte et al., 2019). VEGF-A is upregulated by hypoxia and leads to sprouting angiogenesis in interstitial areas where blood supply is inadequate. After initial vessel structures have been established, the vessels are filled with blood and undergo further vascular remodeling, including stabilization, diameter adjustment, and regression, resulting in a proper vascular network (Jones et al., 2006; Jones, 2011; Tanaka and Laurindo, 2017). Blood flow is particularly important in vessel development after the initial vessels are formed. Blood-derived factors may also have some roles in this process. Among the various blood-derived factors, lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), the two major bioactive lysophospholipids, have been suggested to be potential angiogenic factors. S1P is present in the bloodstream at a high concentration ($\sim 1 \mu$ M). It contributes to vascular stabilization by strengthening endothelial cell-cell adhesion via several G protein-coupled receptors (GPCR) specific to S1P (Yanagida and Hla, 2017). LPA has also been implicated in embryonic blood vessel formation because knockout mice of an enzyme involved in LPA synthesis (autotaxin (ATX)) and LPA receptors (LPA₄ and LPA₆) showed similar vascular defects in embryos around E10.5 (Tanaka et al., 2006; van Meeteren et al., 2006; Koike et al., 2009; Kano et al., 2019; Yasuda et al., 2019).

The vascular plexus is a fine structure of tubes interconnected with each other and is distributed in many normal tissues, including the brain, liver, and lymph node, and also in pathophysiological conditions (Pearce, 2006; Restrepo et al., 2015; Uhl et al., 2016). Despite its common presence, the molecular mechanisms involved in forming and maintaining the plexus structure are not fully understood. The most analyzed model of the venous plexus is the caudal vein plexus (CVP) in zebrafish (Wiley et al., 2011; Mouillesseaux et al., 2016; Goetz et al., 2014; Xie et al., 2018; Karthik et al., 2018; Nagasawa-Masuda and Terai, 2017; Choi et al., 2011; Wakayama et al., 2015). The CVP transiently develops during embryonic development in zebrafish. During zebrafish development, the caudal vein (CV), which is the source of the CVP, arises near the caudal aorta (CA) by 24 h post fertilization (hpf) (Herbert et al., 2009). The CVP is then formed by the synergistic interaction of sprouting angiogenesis and intussusceptive angiogenesis, in which the sizable primitive CV undergoes morphological changes to form fine and interconnected vessels (Karthik et al., 2018). Several preceding reports indicated that factors affecting the actin filament organization, including blood flow (Goetz et al., 2014; Xie et al., 2018; Karthik et al., 2018), Yap/Ctgf (Nagasawa-Masuda and Terai, 2017), HMG-CoA reductase (activates RhoA by geranylgeranylation) (Choi et al., 2011), and Bmp/Cdc42 (Wakayama et al., 2015) regulated the CVP formation. These studies also suggest that factors that alter

¹Graduate School of Pharmaceutical Sciences, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

CellPress

²Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3, Aoba, Aramaki, Aoba-ku, Sendai 980-8578, Japan

³AMED-LEAP, Japan Agency for Medical Research and Development, 1-7-1 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan

⁴Department of Molecular Pathophysiology, Institute of Advanced Medical Sciences, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan

⁵Lead contact

*Correspondence: jaoki@mol.f.u-tokyo.ac.jp https://doi.org/10.1016/j.isci. 2021.103254





the morphology of endothelial cells are involved in CVP formation by regulating the dynamics of actin fibers. Other endothelial cell morphology-altering factors, particularly those that regulate actin fibers, are potential regulators of CVP formation.

ATX is a secreted lysophospholipase D (lysoPLD) that produces a bioactive lipid, lysophosphatidic acid (LPA) from lysophospholipids such as lysophosphatidylcholine (LPC) (Umezu-Goto et al., 2002). LPA produced by ATX, in turn, activates six G protein-coupled receptors (GPCRs, LPA₁₋₆) and exerts various path-ophysiological roles, including embryo implantation (Ye et al., 2005; Aikawa et al., 2017), development of endometriosis (Kowalczyk-Zieba et al., 2019), fibrosis of lung (Tager et al., 2008; Swaney et al., 2010) and kidney (Sakai et al., 2019), and neuropathy pain (Inoue et al., 2004, 2008). ATX and LPA receptors also have a variety of biological functions during development. LPA₁ knockout (KO) mice showed impaired brain development (Estivill-Torrus et al., 2008) and chondrogenesis (Nishioka et al., 2016). ATX KO mice showed defects in the formation of vascular systems and died at embryonic day 9.5–10.5 (Tanaka et al., 2006; van Meeteren et al., 2006; Koike et al., 2009). More recently, double knockout mice of $G\alpha_{13}$ -coupling LPA₄ and LPA₆ were reported to have a phenotype (embryonic lethality and a defective vascular system) similar to that of ATX KO mice (Kano et al., 2019; Yasuda et al., 2019).

Interestingly, endothelial cell-specific knockout of $G\alpha_{13}$ led to a similar embryonic lethality in mice (Ruppel et al., 2005). In addition, in cultured endothelial cells (HUVECs), LPA induced dramatic morphological changes by inducing actin stress fiber formation via LPA₆ and the downstream signaling proteins, $G\alpha_{13}$, RhoA, and Rho kinase (Yukiura et al., 2015). These observations suggest that LPA produced by ATX has a critical role in the formation of embryonic blood vessels through LPA₄ and LPA₆ by regulating endothelial cell shape and that this role is mediated by $G\alpha_{13}$, RhoA, Rho kinase, and the resulting actin fiber modification. In addition, LPA₄/LPA₆ and downstream $G\alpha_{13}$ signaling have been suggested to positively regulate Yap/Taz transcription factors (Yasuda et al., 2019). These transcription factors induce endothelial cell sprouting, possibly by down-regulating β -catenin and Notch ligand DLL4 (Yasuda et al., 2019). Although LPA is a crucial regulator of actin fibers in endothelial cells, its precise role in angiogenesis through the actin fiber modification is obscure. A detailed *in vivo* analysis of endothelial cell dynamics would provide a clue to understanding the role of LPA signaling. However, the mouse model is not suitable for such studies because of the difficulty of observation and manipulation.

The ATX-LPA receptor axis is well conserved among vertebrates, including zebrafish (Fukushima et al., 2015; Yukiura et al., 2011). In zebrafish, genes encoding LPA receptor (LPA₁-LPA₆) and ATX are highly conserved, showing 30 to 90% homology to the corresponding mammalian orthologs. In addition, the biochemical functions of zebrafish LPA receptors and ATX are well conserved (Yukiura et al., 2011). Zebra-fish are well suited for developmental studies because of their small size, transparency of embryos, and development outside of the mother (Lawson and Wolfe, 2011; Hogan and Schulte-Merker, 2017). Another advantage of using zebrafish is that transgenic (*Tg*) zebrafish, which make it possible to observe organ development in embryonic stages, are available. For example, fluorescent zebrafish *Tg* (*fli1:EGFP*) make it possible to monitor blood vessel formation processes in different developmental stages (Isogai et al., 2003).

Morpholino (MO)-based knockdown approaches in zebrafish have shown that ATX-LPA signaling plays essential roles in blood vessel formation (Yukiura et al., 2011), lymphatic vessel formation (Lee et al., 2008), and oligodendrocyte differentiation (Yuelling et al., 2012). However, a recent study comparing the phenotypes of MO-induced gene knockdown embryos and gene mutants revealed the vulnerability of the MO-based tools to dissect the gene functions because of the off-target effects of MO (Kok et al., 2015). Recently, LPA₁ KO embryos were shown to have abnormalities in chondrogenesis (Nishioka et al., 2016) and LPA₃ receptor was shown to be involved in megakaryopoiesis (Lin et al., 2018). However, neither mutant showed any abnormalities in angiogenesis.

We previously biochemically characterized zebrafish ATX (ATXa), which at that time was a unique ATX gene in the zebrafish gene database (Yukiura et al., 2011). Accordingly, we generated KO fish of *atxa* using the TALEN system. Surprisingly, the resulting *atxa* mutant developed with an intact vascular system. Notably, ATXa KO zebrafish had plasma ATX activity nearly equal to that of wild-type fish. This finding led to the discovery of a second ATX gene, *atxb*, in zebrafish (Kise et al., 2019). Both *atxa* and *atxb* encoded functional ATX proteins, and an ATX inhibitor ONO-8430506 developed against mammalian ATX efficiently blocked

iScience

Article





Figure 1. Abnormal caudal vein plexus (CVP) structure in atxb mutant embryos

(A) Schematic diagram of blood vessels in the caudal region of the zebrafish embryo. DLAV, dorsal longitudinal anastomotic vessel; ISV, intersegmental vessel; CA, caudal aorta; dCVP, dorsal part of CVP; vCVP, ventral part of CVP. (B) Projection view of confocal z stack images of CVP from the lateral side of wild-type $(atxa^{+/+}/atxb^{+/+})$, atxb heterozygous $(atxa^{+/+}/atxb^{+/-})$ and homozygous $(atxa^{+/+}/atxb^{-/-})$, atxa homozygous $(atxa^{-/-}/atxb^{+/+})$, atxa





Figure 1. Continued

homozygous atxb heterozygous ($atxa^{-/-}/atxb^{+/-}$) and atxa/atxb double-homozygous ($atxa^{-/-}/atxb^{-/-}$) mutant embryos at 36 hpf. Enlarged images of the area surrounded by squares are positioned on the right side. Arrowheads show the column structure formed between vessels. Scale bar, 100 μ m.

(C–F) Quantitative evaluation of CVP's morphology from confocal images from the lateral side. Ten somites from the end of the yolk extension were evaluated. Data were shown as mean with SD of sixteen $atxb^{+/+}$ and six $atxb^{-/-}$ embryos. p value was calculated by the student's t test (*p < 0.05; **p < 0.01; n.s., no significance). (C) The total area of columns in the ten somites was quantified by Zen 2 (blue edition) software and shown. (D) The total number of columns present across the ten somites. (E) The average area of columns (Total area of columns (C) divided by the number of columns (D)). (F) Total vessel area.

(G) The cross-sectional single-plane images of CA, dCVP and vCVP from wild-type ($atxb^{+/+}/atxb^{+/+}$), ATXa KO ($atxa^{-/-}/atxb^{+/+}$) and ATXb KO ($atxb^{+/+}/atxb^{-/-}$) embryos at the positions indicated by yellow lines in the upper lateral view are shown in the lower side. Ten somites from the end of the yolk extension were analyzed. Somites a to e and somites f to j were defined as anterior and posterior somites, respectively. Arrowheads indicate the column structures in the lateral images. Arrows, hollow arrowheads and hollow arrows in the cross-sectional images indicate the CA, dCVP and vCVP, respectively. Note that in $atxb^{-/-}$ embryos CA and dCVP were not separated in the posterior part. Scale bar, 100 µm. (H–J) Quantitative evaluation of CVP's morphology from the cross-sectional images. Data were shown as mean with SD of sixteen $atxb^{+/+}$ and six $atxb^{-/-}$ embryos. p value was calculated by the student's t test (**p < 0.01; ***p < 0.001). The graphs show the average number of separated vessels in the cross-sectional images from ten somites (somites a to j, H), five anterior somites (somites a to e, I), and five posterior somites (somites f to j, J).

(K) Projection views of confocal z stack images from lateral side and cross-sectional images of CVP at 36 hpf. Wild-type embryos were treated with ATX inhibitor, ONO-8430506, from 25 to 36 hpf. Schematic diagrams of the protocol are also shown in the upper side. Scale bar, 100 μm.

See also Figures S1, S5, and S6, Videos S1 and S2.

the lysoPLD activity of the two ATX proteins (Kise et al., 2019). In this study, to explore the biological roles of ATX in zebrafish, we generated the *atxb* and *atxa/atxb* double zebrafish mutants. As a result, we unexpectedly found that ATXb has a role in forming and maintaining a specific vessel, i.e., caudal vein plexus (CVP)

RESULTS

Establishment of atxb mutant fish

First, we generated ATXb mutants and ATXa/ATXb double mutants using the genome editing technology CRISPR from the previously established ATXa mutant (Kise et al., 2019). We established two lines of ATXb hetero mutants ($atxb^{ro1}$ and $atxb^{ro2}$ alleles) and two lines of ATXa/ATXb double-hetero mutants ($atxb^{ro1}$ and $atxb^{ro2}$ alleles) carrying a frameshift mutation in amino acid residues in the vicinity of threonine¹⁹⁵ of ATXb, which is predicted to be the catalytic center (Yukiura et al., 2011; Kise et al., 2019) (Figure S1). Of note, both mutant ATXb proteins encoded by the two mutant alleles ($atxb^{ro1}$ and $atxb^{ro2}$) lack the catalytic center, which is essential for the catalytic activity of the ATX, which shows that the ATXb products produced from the mutant alleles lack catalytic activity. Next, we determined the genotypes of adult fishes obtained by crossing ATXa/ATXb double mutants ($atxa^{-/-}/atxb^{+/-} \times atxa^{+/-}/atxb^{+/-}$). The ratio of the resulting six genotypes ($atxa^{+/-}/atxb^{+/+}$, $atxa^{+/-}/atxb^{+/-}$, $atxa^{-/-}/atxb^{+/+}$, $atxa^{-/-}/atxb^{+/-}$, and $atxa^{-/-}/atxb^{-/-}$) roughly followed the Mendelian law (Figure S2).

Little ATX (lysoPLD) activity was detected in the plasma from ATXa/ATXb DKO adult fishes, whereas a small amount of lysoPLD activity (about 10% of that of wild-type zebrafish) was detected in the plasma of ATXb KO ($atxa^{+/+}/atxb^{-/-}$) fish (Figure S3). These results indicate that ATXb and ATXa are the major and the minor ATXs in zebrafish, respectively. They also suggest that zebrafish do not have a third ATX gene. Thus, we unexpectedly found that loss of ATX was not lethal during development in zebrafish unlike in mice.

Abnormal caudal vein plexus (CVP) structure in the atxb mutant

We noticed that at 36 hpf ATXb KO ($atxb^{-/-}$) embryos (both ro1 and ro2 lines) showed an abnormal blood flow, especially in the caudal part. In ATXb KO embryos, blood cells flowed very slowly through the veins and did not reach the tail (Video S1 and S2). Of note, the heart rates were comparable between wild-type and ATXb KO embryos (Figure S4). To visualize vessels, we crossed the ATXb and ATXa/ATXb mutants with a *Tg* lineage, *Tg(fli1:EGFP)*, in which EGFP is expressed specifically in endothelial cells, and analyzed the process of vessel formation during development. At 36 hpf, vessels in the posterior parts consisted of the dorsal longitudinal anastomotic vessel (DLAV), intersegmental vessel (ISV), caudal aorta (CA), and caudal vein plexus (CVP) from the dorsal to the ventral sides (Figure 1A), as was reported previously (Isogai et al., 2001). At this stage, CVP consists of dorsal (dCVP) and ventral (vCVP) parts (Karthik et al., 2018;



Nagasawa-Masuda and Terai, 2017; Wakayama et al., 2015) (Figure 1A). Time-lapse analyses of the resulting embryos revealed an obvious abnormal vessel structure at 36 hpf in embryos lacking ATXb regardless of the genotype of *atxa* (Figure 1B), i.e., the same vascular phenotype was observed in ATXa/ATXb DKO ($atxa^{-/}/atxb^{-/-}$ ro1 line) embryos (Figure 1B) and ATXb KO embryos (both ro1 (Figure 1B) and ro2 lines (Figure S5)). CVP at this stage had column structures, which are endothelial cell-free stromal areas in the CVP (Figure 1A). Wild-type and $atxb^{+/-}$ embryos ($atxa^{+/+}/atxb^{+/+}$, $atxa^{-/-}/atxb^{+/+}$, $atxa^{+/+}/atxb^{+/-}$ and $atxa^{-/-}/atxb^{+/-}$) had abundant column structures (Figure 1B, arrowheads). On the other hand, ATXb KO embryos ($atxa^{+/+}/atxb^{-/-}$ and $atxa^{-/-}/atxb^{-/-}$) had fewer and smaller column structures (Figure 1B). Of note, the column structures were seldomly observed in the anterior part in the ATXb KO embryos (Figure 1B). Because we did not observe significant changes in the CVP phenotype among the ATXb KO (*ro1* line), ATXb KO (*ro2* line) and ATXa/ATXb DKO (*ro1* line) embryos (Figure 1B), the subsequent analysis was essentially focused on ATXb KO (*ro1* line) fishes. Quantitative analysis of the column structure in ATXb KO confirmed that the ATXb KO had fewer and smaller column structure (Figures 1C–1E). The total vessel areas as judged by the projection views from the lateral sides (Figure 1B) were comparable between $atxb^{-/-}$ and $atxb^{+/+}$ embryos (Figure 1F).

Cross-sectional views of the CA and CVP showed that they were finely subdivided and separated from each other in wild-type and ATXa KO embryos (Figure 1G, first and second lines, lower panel). By contrast, such vessel subdivision and separation were not obvious in ATXb KO embryos (Figure 1G, third line, lower panel). For example, although CA was lumenized and independent from CVP in the anterior parts (Figure 1G, lower panel, somites a–d), it was continuous with CVP on the posterior parts (Figure 1G, lower panel, somites a–d), it was continuous with CVP on the posterior parts (Figure 1G, lower panel, somites e–j). The abnormal CA and CVP structures were also confirmed by the observation that a number of blood cells return to the vein without reaching the tail (Video S2), showing that ATXb KO embryos had an abnormal aorta and vein that were not separated as independent vessels. A similar but more severe lack of vessel subdivision was also observed in the anterior parts of CVP (Figure 1G, bottom left, lower panel). In somite a, for example, dCVP and vCVP fused to form a large sac-like vessel, although CA was separated from CVP. In somites b–e, dCVPs fused to form a large sac-like vessel, although they were separated from vCVP (Figure 1G, bottom line, lower panel). We counted the number of subdivided vessels and confirmed that the ATXb KO embryos had a less subdivided CVP, especially in the anterior parts (Figures 1H–1J).

We also examined the CVP formation when ATX was inactivated pharmacologically. The ATX inhibitor ONO-8430506, which was recently developed against mammalian ATX (Iwaki et al., 2020), was found to inhibit both ATXa and ATXb (Kise et al., 2019). When fertilized eggs were treated with the ATX inhibitor from 25 hpf, a CVP phenotype similar to that in ATXb KO embryos was observed at 36 hpf (Figures 1K and S6), confirming that the CVP phenotype in ATX mutants is not an off-target effect.

We further observed vessel formation in ATXb KO embryos from 36 hpf back in time. In wild-type embryos, a primitive CV has formed from the CA by 25 hpf (Figures 2A and 2B). Then, from the primitive CV fine dCVP and vCVP were formed by 29 hpf, especially in somite b-f (Figure 2B; Video S3 (lateral view) and S4 (cross-sectional view)). In this process, ventral endothelial cells in the primitive CV had multiple protrusions (sprouting), which anastomosed to form a finely subdivided CVP and multiple column structures (Video S3), or a primitive CV divided into multiple compartments by intussusception (Video S4). By contrast, in ATXb KO embryos, such transformation of vessels was seldom observed (Figures 2A and 2C; Videos S5 (lateral view) and S6 (cross-sectional view)), and as a result, subdivision of vessels (CVP formation) was mostly absent in ATXb KO embryos (Figures 2A, 2C, and 2D). It should be noted here that the extension of endothelial cells (sprouting) and CVP formation were less affected in the posterior part of ATXb KO embryos (Figure 2C and Video S5 (lateral view)).

Malformation of CVP in *lpar6a/lpar6b* and *gna13a/gna13b* double mutant embryos and in embryos treated with inhibitors for $G\alpha_{13}$ signaling

Previous *in vitro* analyses using endothelial cells have shown that LPA induces actin stress fiber formation via LPA₆ receptor and downstream RhoA and Rho kinase (Yukiura et al., 2015). Furthermore, LPA₄/LPA₆ receptor DKO mice (Yasuda et al., 2019), $G\alpha_{13}$ KO mice (Ruppel et al., 2005), and Rho kinase KO mice (Kamijo et al., 2011) commonly exhibited an embryonic lethal phenotype similar to that of ATX KO mice (Tanaka et al., 2006; van Meeteren et al., 2006), because of defects of embryonic vessel formation. Therefore, we hypothesized that these molecules might also function downstream of ATX in zebrafish, contributing to CVP formation. To test this possibility, we generated LPA₄, LPA₆a, and LPA₆b KO fishes along with their







Figure 2. Abnormal vessel segmentation in ATXb KO embryos

(A) Schematic diagrams explaining the phenotype of ATXb KO embryos. DA and CVP are drawn in red and blue, respectively. The diagrams for crosssectional images at the yellow dot line (lower panel) are shown, indicating that ATXb KO embryos have large and sac-like CVP.

(B and C) Sequential time-lapse images of wild-type $(atxb^{+/+})$ (B) and $atxb^{-/-}$ (C) embryos at the indicated time points. Both projection views from the lateral side (upper panel) and cross-sectional images (lower panel) are shown. Enlarged images of the area surrounded by squares in lateral images are positioned in the right side (upper panel). In $atxb^{+/+}$ embryos, endothelial cells (ECs) sprout ventrally from the CV (dCVP primordia) and anastomose each other (upper panel). Arrowheads and hollow arrowheads indicate sprouting and anastomosing (rejoining) EC cells, respectively. The sectional images at the six somites (a to f) (lower panel) show that the subdivision of dCVP proceeds in time dependent manner. In this process, ECs sprout into the CV lumen and form a cross-linked (bridging) structure (shown by arrows). Then, CV constriction and subdivision proceed in parallel. In an $atxb^{-/-}$ embryo (C), we observed extremely little vessel subdivision, which results in remaining of large lumens. Note that both EC sprouting and the sign of forming the bridging structure are still observed, even less frequently. Scale bars, 100 µm.

(D) Numbers of separated vessels surrounded by endothelial cells in a cross section (somite a–f in Figures 2B and 2C) at the indicated timepoints. Four wild-type ($atxb^{+/+}$) and five ATXb homozygous ($atxb^{-/-}$) embryos were evaluated. All data were expressed as means and SD. p value was calculated by the student's t test (*p < 0.05; **p < 0.01; n.s., no significance). See also Videos S3–S6.

See also Videos 53-56.

multiple KO fishes as well as $G\alpha_{13}a$ and $G\alpha_{13}b$ KO, and $G\alpha_{13}a/G\alpha_{13}b$ DKO fishes using TALEN and CRISPR Cas9 systems (Figures S7 and S8). Among zebrafish embryos with various genotypes obtained by intercrossing LPA₄/LPA₆a/LPA₆b triple mutants ($lpar4^{-/-}/lpar6a^{-/-}/lpar6b^{-/-} \times lpar4^{+/-}/lpar6a^{+/-}/lpar6b^{+/-}$) embryos showed the CVP phenotype similar to that observed in the ATX mutants regardless of the LPA₄ genotype (Figures 3A–3C). $lpar4^{-/-}/lpar6a^{+/-}/lpar6b^{+/-}$ embryos did not show the phenotype (Figure 3D). We also determined the number of separated vessels in cross-sectional views (Figure 3E), showing that LPA₆ (both LPA₆a and LPA₆b) but not LPA₄ were needed for proper CVP formation. Essentially the same CVP phenotype was observed in $G\alpha_{13}a/G\alpha_{13}b$ DKO fishes ($gna13a^{-/-}/gna13b^{-/-}$) (Figures 4A–4C).





Figure 3. Similar abnormal CVP structure in Ipar6a/Ipar6b double mutant embryos

(A–D) Sequential time-lapse images of control ($lpar4^{+/-}/lpar6a^{+/-}/lpar6b^{+/-}$) (A) and $lpar4^{+/-}/lpar6a^{-/-}/lpar6b^{-/-}$ (B), $lpar4^{-/-}/lpar6a^{-/-}/lpar6a^{-/-}/lpar6b^{-/-}$ (C), and $lpar4^{+/-}/lpar6a^{+/-}/lpar6a^{+/-}/lpar6a^{+/-}/lpar6a^{+/-}/lpar6a^{+/-}/lpar6a^{-/-}/lpar6b^{+/-}$ (D) embryos at the indicated time points. Both projection views from the lateral side (upper panel) and sectional images (lower panel) are shown. Enlarged images of the area surrounded by squares are positioned in the right side (upper panel). In all embryos, endothelial cell (EC) sprouts and their anastomosis were observed although less frequent in $lpar4^{+/-}/lpar6a^{-/-}/lpar6b^{-/-}$ (B) and $lpar4^{-/-}/lpar6a^{-/-}/lpar6b^{-/-}$ (C) embryos. Arrowheads and hollow arrowheads indicate sprouts and anastomosed (re-joined) sprouts, respectively. Cross-linked structure formed in lumen is pointed with arrows. Vessel subdivision was significantly attenuated in $lpar4^{+/-}/lpar6a^{-/-}/lpar6b^{-/-}$ (B) and $lpar4^{-/-}/lpar6a^{-/-}/lpar6b^{-/-}$ embryos. (C), which





Figure 3. Continued

resulted in the remaining large lumens, as was observed for $atxb^{-/-}$ mutants. Note that both EC sprouting and the sign of forming the bridging structure are still observed, even less frequently. Scale bars, 100 μ m.

(E) Numbers of separated vessels surrounded by endothelial cells in a cross section (somite a-f in Figures 3A–3D) at the indicated timepoints. Four or five embryos with genotypes shown were evaluated ($lpar4^{+/-} lpar6a^{+/-} lpar6b^{+/-} n = 4$, $lpar4^{-/-} lpar6a^{+/-} lpar6b^{+/-} n = 5$, $lpar4^{+/-} lpar6a^{-/-} lpar6b^{-/-} n = 5$, $lpar4^{-/-} lpar6a^{-/-} lpar6b^{-/-} n = 5$, $lpar4^{-/-} lpar6a^{-/-} n = 4$). All data were expressed as means and SD. p value was calculated by the student's t test (*p < 0.05; **p < 0.01; ***p < 0.001; n.s., no significance).

See also Figure S7.

We further examined whether inhibition of downstream signaling of $G\alpha_{13}$ led to CVP malformation. Treatment of embryos with inhibitors for Rho kinase (Rockout) and a myosin II (Blebbistatin) after 24 hpf caused CVP abnormalities similar to those observed in ATXb KO, LPA₆a/LPA₆b DKO, and $G\alpha_{13}a/G\alpha_{13}b$ DKO embryos (Figures 4D–4G). These analyses strongly suggested that the ATX-LPA₆-G α_{13} axis regulated CVP formation by activating downstream RhoA and Rho kinase and the following actin polymerization.

To confirm that the actin cytoskeleton was really affected by ATX inactivation, we used a transgenic (Tg) zebrafish line (*Tg*(*fli1:lifeact-mCherry*)) expressing mCherry-tagged lifeact, a small actin-binding peptide, under the control of the endothelial cell-specific *fli1* promoter, which enabled the real-time observations of actin dynamics. When the ATX inhibitor ONO-8430506 was administered at 25 hpf, many punctate signals were detected at 36 hpf when abnormal CVP structure was observed, which were never observed in control untreated embryos (Figure S9). This analysis revealed that an ATX-LPA axis actually regulates actin cytoskeleton formation in CVP.

ATX contributes to the maintenance of CVP

Administration of ATX inhibitors enabled us to verify the function of ATX at any given time. Interestingly, unlike DMSO-treated control embryos (Figures 5A and 5B; Videos S7 and S8), administering ATX inhibitor at 36 hpf, when the CVP had pre-formed, caused many fine vessels to fuse to form larger vessels (Figures 5A and 5C; Videos S9 and S10). The fusion of fine vessels was evident in the anterior parts, and was consistent with the observation that $atxb^{-/-}$ embryos had a large and fused CVP in the anterior parts (Figures 1B and 1G). Administration of ONO-8430506 also induced rapid regression of the column structures (Figures 5A, 5D and 5E). The column structures as judged by the areas did not change during the 6 h in DMSO-treated embryos, whereas they rapidly shrank in embryos treated with ONO-8430506. Of note, morphological changes in these CVPs started in as little as 10 min and were clearly observed 20 min after the administration of ATX inhibitor (Figures 5F and 5G), which suggests that the ATX inhibitor's effect did not involve gene transcription. Although CVP formation was reported to be inhibited by reduced blood flow (Xie et al., 2018), the videos (Videos S11 and S12) strongly suggest that the regression of CVP by ATX inhibition was not due to inhibition of blood flow. We tried to observe the actin cytoskeleton when the column structures in the CVP regressed following ATX inhibition. When Tg(fli1:lifeact-mCherry) embryos were treated with the ATX inhibitor ONO-8430506 at 36 hpf, a number of punctate signals were observed 30 min after its administration (Figure S10). The punctate signals were similar to those observed when embryos were treated with the ATX inhibitor at 25 hpf (Figure S9). Together, these data suggested that ATX had a role in maintaining the fine vessel structures, in addition to a role in CVP formation, possibly via the actin cytoskeleton.

LPA₆-dependent constriction of the caudal vein plexus (CVP) by an LPA stable analog

We then asked how the ATX-LPA₆ axis contributes to the formation and maintenance of subdivided vessels. To answer this question, we injected OMPT (1-oleoyl-2-methyl-*sn*-glycero-3-phosphothioate), a stable and potent LPA₆ agonist (Yanagida et al., 2009; Jiang et al., 2013), into the fish embryos and observed the vessels. To assess whether OMPT reached each part of the vessel, we mixed a dye (Evans blue) with the OMPT solution and injected the mixture in the vicinity of the heart. At 36 hpf when CVP was pre-formed, as soon as OMPT reached CVP, the CVP rapidly shrank (Figure S11B; Video S14), whereas the shrinkage was less in the vehicle control (Figure S11A; Video S13).

We then tried to evaluate OMPT-induced vasoconstriction in LPA₆a/LPA₆b DKO embryos. However, because the CVP structures were quite different between LPA₆a/LPA₆b DKO and control embryos at 29 hpf (Figure 3), we could not evaluate the effect of OMPT on vasoconstriction at this time point. At 25 hpf, although the vessel structures in both wild-type and *lpar6a^{-/-}/lpar6b^{-/-}* embryos were similar, the heart beats weakly, and the injected OMPT did not circulate well in the bodies (data not shown).





Figure 4. Similar abnormal CVP structure in *gna13a/gna13b* double mutant embryos and embryos treated with inhibitors of actin stress fiber formation

(A, B, and D) All images are projection views of confocal z stack images and cross-sectional images of CVP. Scale bars, 100 μ m. For (D), inhibitors were added at 24 hpf and images were taken at 36 hpf. (A and B) Images of control (gna13a^{+/-}/gna13b^{+/-}) and gna13a/gna13b double KO (gna13a^{-/-}/gna13b^{-/-}) embryos were taken from 25 hpf to 29 hpf. Arrowheads and hollow arrowheads indicate sprouts and anastomosed (re-joined) sprouts, respectively. Cross-linked structure formed in lumen is pointed with arrows.





Figure 4. Continued

(C) Numbers of separated vessels surrounded by endothelial cells in a cross section (somite a–f in A and B) at the indicated timepoints. Four $gna13a^{+/-}/gna13b^{+/-}$ and three $gna13a^{-/-}/gna13b^{-/-}$ embryos were evaluated. All data were expressed as means and SD. p value was calculated by the student's t test (*p < 0.05; **p < 0.01; n.s., no significance). (D) Embryo treated with DMSO only (negative control), ROCK inhibitor (Rockout), or inhibitor of stress fiber formation (Blebbistatin). Note that the vessel subdivision is rarely observed in the anterior somites in $gna13a^{-/-}/gna13b^{-/-}$ embryos and in embryos treated with Rockout and Blebbistatin.

(E–G) Numbers of separated vessels surrounded by endothelial cells in a cross section (somite a–f in D) from three to ten embryos (DMSO n = 10, Rockout n = 3, Blebbistatin n = 8). The anterior somites a–e (E), the posterior somites f–j (F) and all somites (a–j) (G) were evaluated. All data were expressed as means and SD. p value was calculated by the student's t test (***p < 0.001). See also Figure S8.

When treated with the ATX inhibitors at 25 hpf, embryos had similar enlarged CVP structures at 36 hpf, regardless of the genotype (Figures 6A–6D, time 0 s). Therefore, we treated the embryos with ATX inhibitor at 25 hpf and injected OMPT at 36 hpf. In wild-type embryos, injection of OMPT but not PBS (vehicle control) at 36 hpf rapidly induced vasoconstriction of the CVP (Figures 6A and 6B; Videos S15 and S16). The OMPT-induced rapid CVP constriction was observed in *lpar6a^{+/-}/lpar6b^{+/-}* but not in *lpar6a^{-/-}/lpar6b^{-/-}* embryos (Figures 6C and 6D; Videos S17 and S18). Quantitative analysis of the long axis of the vessel cross-section confirmed that OMPT-induced vasoconstriction is significantly suppressed in *lpar6a^{-/-}/lpar6b^{-/-}* embryos (Figures 6E and 6F). We also confirmed that pretreatment of the embryos with Rockout significantly inhibited the OMPT-induced vasocontraction, indicating that the vasocontraction is ROCK-dependent (Figures 6G–6I, and Videos S19 and S20). In addition, treatment of *Tg(fli1:lifeact-mCherry)* with OMPT caused the punctate signals to disappear (Figure S12). These punctate signals were induced by treatment of ATX inhibitors (Figures S10 and S12). These analyses revealed that OMPT-induced activation of LPA₆ and the downstream Rho kinase led to CVP constriction via modification of the actin cytoskeleton.

CVP formation induced by blood flow is dependent on ATX

Several studies have shown that a similar CVP malformation was induced when the blood flow was suppressed (Goetz et al., 2014; Xie et al., 2018; Karthik et al., 2018). Because inhibition of the ATX-LPA₆ axis disturbed both CVP formations and blood flow at about the same time (Figure 1; Videos S1, S2, S3, S4, S5, and S6), we attempted to elucidate the relationship between the ATX-LPA₆ axis and blood flow. Treatment of zebrafish embryos with 2,3-butanedione-2-monoxime (BDM) at 24 hpf, which is known to lower the heart rate, rapidly induced a marked reduction in the heart rate and blood flow resulted in the formation of abnormal CVP structures (non-subdivided vessels) at 34 hpf (Karthik et al., 2018; Nagasawa-Masuda and Terai, 2017) (Figure 7A). When BDM was removed at 34 hpf, the blood flow resumed with the recovery of heart rate (Video S21), and the CVP started to subdivide to form fine vessels at 37 hpf (Figure 7B). When BDM was removed but ONO-8430506 was added at 34 hpf, subdivision of the CVP was significantly suppressed (Figures 7C and 7D). It should be noted that the blood flow resumed in the presence of ONO-8430506 (Video S22), which shows that ATX has a role in the formation of the CVP caused by the resumption of blood flow.

DISCUSSION

The ATX-LPA axis is essential for blood flow-induced CVP formation

In a developing embryo, after the initial vessel structures have been established, blood flow is particularly important in vascular remodeling, which includes stabilization, diameter adjustment, and regression. In this study, we showed that an ATX-LPA₆ axis regulates CVP formation in concert with blood flow stimulation. We found that treatment with ATX inhibitors before CVP formation inhibited CVP formation, and treatment with ATX inhibitors after CVP formation prevented the maintenance of CVP structures, including column structures. Furthermore, these abnormalities in the formation and maintenance of the CVP were observed when blood flow was inhibited. Of note, the CVP formation caused by the resumption of blood flow was markedly inhibited by ONO-8430506 (Figure 7C). Thus, ATX, and possibly downstream LPA₆ signaling, was shown to be essential for the blood flow-driven CVP formation. This result also suggests that either (1) LPA production by ATX is dependent on the blood flow or (2) the blood flow-induced CVP formation is stimulated by the presence of LPA. The former seems unlikely, because LPA production proceeds satisfactorily in a static tube. Regarding the latter explanation, LPA was found to sensitize the shear stress-induced Ca²⁺ response in endothelial cells (Ohata et al., 2011). Thus, it is reasonable to assume that LPA produced by ATX accelerates the blood flow-induced CVP formation through LPA₆ in zebrafish







Figure 5. ATX has a role in maintaining CVP structure

(A) Schematic diagram explaining the effect of ATX inhibition on CVP structure. DA and CVP are drawn in red and blue, respectively. The diagram for the cross-sectional image at the yellow dot line (right panel) is shown.

(B and C) Projection views of confocal z stack images and cross-sectional images of CVP during 36–42 hpf. Wild-type embryos were treated with ATX inhibitor, ONO-8430506, from 36 to 42 hpf and confocal CVP images were taken at indicated time points. Schematic diagrams of the protocol are also shown in the upper side. Images from DMSO (B) or ONO-8430506 (C)-treated embryos are shown. Time-lapse images were shown every 30 min. Scale bars, 100 μ m. (D and E) ATX inhibitor treatment induces rapid shrinkage of column structure. (D) Enlarged images of the column structure in the area surrounded by squares in Figures 5B and 5C, showing that the column structure rapidly regresses in a time-dependent manner after ATX inhibitor treatment. (E) Quantitative analysis of the column shrinkage after ATX inhibitor treatment (DMSO n = 4, ONO-8430506 n = 3). Time-dependent changes in the column area. The column area at indicated time points was divided by the column area at 36 hpf, and the resulting relative column area was shown. All data were expressed as means and SD. p value was calculated by the student's t test (*p < 0.05; **p < 0.01; ***p < 0.001).

(F and G) Rapid CVP expansion in the early phase after ATX inhibitor treatment. At 36 hpf, wild-type embryos were treated with ATX inhibitor, and timedependent changes of CVP structure in cross-sectional images were taken every 10 min. Arrowheads show the expanded CVP vessels. See also Figure S10 and Videos S7–S12.

embryos. This is supported by the finding that CVP formation was accelerated by increasing the blood flow (Karthik et al., 2018). *In vitro* analysis using cultured endothelial cells is needed to clarify how LPA stimulation regulates the morphological changes of endothelial cells induced by blood flow (i.e., induced by shear stress).





Figure 6. LPA₆-dependent constriction of caudal vein plexus (CVP) by an LPA stable analog

(A and B) Constriction of CVP induced by OMPT. At 25 hpf, wild-type embryos were treated with ATX inhibitor, ONO-8430506 (100 μ M), for eleven hours. At 36 hpf, the embryos were injected with OMPT in the vicinity of the heart. Time-lapse images are taken every 20 s after the injection. The circulation of OMPT is evaluated by the fluorescence of Evans Blue, which is mixed with OMPT. The time-lapse images show that Evans Blue and thus OMPT pass through CA and then reach CVP gradually after they enter the circulation.

(B) OMPT rapidly induces shrinkage of CVP as soon as it reaches CVP (B), which is never observed in vehicle control (DMSO, A). OMPT also induces the constriction of CA (arrowheads) (B). Scale bars, 50 μ m.

(C and D) Constriction of CVP induced by OMPT in *lpar6a^{-/-}/lpar6b^{-/-}* embryos. Treatment with ATX inhibitor, OMPT injection, and analyses were performed as in A and (B). OMPT rapidly induces shrinkage of CVP in *lpar6a^{+/-}/lpar6b^{+/-}* embryos (C), which was significantly weakened in *lpar6a^{-/-}/lpar6b^{-/-}* embryos (D). Scale bars, 50 μ m.



Figure 6. Continued

(E and F) Quantitative evaluation of CVP constriction. The length of the CVP long axis was determined using Zen software from the sectional images of confocal z stack images, and the rate of change in CVP long axis was calculated by dividing the length at time 300 s by that at 0 s (E; OMPT vs. vehicle control (DMSO) and F; $lpar6a^{+/-}/lpar6b^{+/-}$ vs. $lpar6a^{-/-}/lpar6b^{-/-}$). Data were shown as means \pm SD of three-vehicle control and three OMPT-injected embryos for A and B, respectively, and four $lpar6a^{+/-}/lpar6b^{+/-}$ and four $lpar6a^{-/-}/lpar6b^{-/-}$ embryos, respectively. p value was calculated by the student's t test (*p < 0.05; ***p < 0.001).

(G–I) Effect of Rho-kinase inhibitor on OMPT-induced vasoconstriction. Thirty-four hpf embryos were pre-treated with Rockout (100 μ M), and OMPT-induced vasoconstriction was evaluated at 36 hpf as in A and B (G, DMSO control and H, Rockout). Scale bars, 50 μ m. (I) Quantitative evaluation of CVP constriction was performed as in (E) and (F). Three embryos treated with DMSO and three embryos treated with Rockout were evaluated. All data were expressed as means and SD. p value was calculated by the student's t test (**p < 0.01).

See also Figures S11, S12 and Videos S13–S20.

The ATX-LPA₆ axis contributes to the formation and maintenance of CVP

In this study, we showed that the ATX-LPA₆ axis contributed to the formation and maintenance of CVP using various zebrafish mutants (ATX, LPA₆, and Ga₁₃) and inhibitors. In embryos of these mutants or those treated with inhibitors, the process of CVP formation was abnormal; especially, the process with subdivision of blood vessels was impaired. On the other hand, treatment of pre-formed CVP with inhibitors resulted in impairment of CVP structure and reversion to a more primitive CVP, i.e., a large and sac-like CVP. Interestingly similar vessel abnormalities were observed in ATX KO (Tanaka et al., 2006; van Meeteren et al., 2006) and LPA₄/LPA₆ DKO (Yasuda et al., 2019) mice, which had numerous large vessels in the yolk sac and brain. Thus, it is likely that the ATX-LPA receptor axis has a conserved role in a wide range of animal species. ATX expression is especially high in typical plexuses such as vessels in the choroid plexus in the brain (Savaskan et al., 2007) and high endothelial venules in the lymph node (Nakasaki et al., 2008). Considering that LPA₆ is expressed widely in endothelial cells (Takara et al., 2017; Yukiura et al., 2015), ATX-LPA₆ may contribute to the formation and maintenance of such vascular plexuses.

In the present zebrafish model, we could not determine the role of LPA₄, because loss of LPA₄ did not affect the CVP phenotype in embryos (Figure 3). In both mammals and zebrafish, the six LPA receptors (LPA₁ to LPA₆) and five sphingosine 1-phosphate (S1P) receptors (S1P₁ to S1P₅) are conserved, whereas some of them are duplicated in zebrafish. Thus, although these lysophospholipid receptors are genetically conserved, they may have slightly different roles in mammals and fish, as was recently reported for S1P receptors (Hisano et al., 2015).

The ATX-LPA₆ axis acts by inducing contractile force in endothelial cells

By directly injecting OMPT, an LPA₆ agonist, into the embryos (Tg(fli1:EGFP)), we attempted to verify how the ATX-LPA₆ axis affects the morphology of endothelial cells. Injection of OMPT induced dramatic changes in the morphology of endothelial cells leading to vasoconstriction in zebrafish embryos and this effect is suppressed in Ipar6a/Ipar6b DKO embryos and embryos treated with ROCK inhibitor (Figure 6). We confirmed that administration of OMPT affected the actin cytoskeleton in CVP (Figure S12). We also previously demonstrated that i.v. administration of LPA in mice induced transient hypertension in an LPA₆/ROCK-dependent manner, possibly by inducing vasoconstriction (Kano et al., 2019). These results suggest that ATX-LPA induces a contractile force on endothelial cells through the LPA₆-G α_{13} -RhoA-ROCK axis and that vasoconstrictive forces somehow contribute to vessel subdivision and maintenance. Time-lapse observations of subdividing primitive vessels in the CVP revealed that they first underwent shrinking and then separated from each other, forming two independent vessels (Figure 2B; Video S4). As shown in Figure 8, we propose that the contractile force in endothelial cells generated by an ATX-LPA₆ axis contributes to the formation (intussusception, vessel shrinkage, and separation) and maintenance of the two vessels. We speculate that LPA acts on blood vessels from the lumen side and generates a force in the inward direction because LPA is known to be a blood-derived factor, and when OMPT, a stable derivative of LPA, is in the blood, it rapidly constricts blood vessels.

ATX-LPA₆ axis acts by reorganizing the actin cytoskeleton through the $G\alpha_{13}$ -RhoA-ROCK pathway

CVP formation is regulated by several factors that affect actin filament organization (Goetz et al., 2014; Xie et al., 2018; Karthik et al., 2018; Nagasawa-Masuda and Terai, 2017; Choi et al., 2011; Wakayama et al., 2015). In various cell types, including endothelial cells, an LPA-G α_{13} signal induced actin fiber modification, thereby altering cell morphology, possibly by modulating the adhesive properties of the cells. In addition, several lines of evidence have suggested that actin fiber modification induced by an LPA-G α_{13} signal stimulates embryonic vessel







Figure 7. Blood flow-induced CVP formation is dependent on ATX

(A) Twenty-four hpf embryos were pre-treated with BDM (12 mM) for ten hours by changing the medium to a medium containing BDM, and at 34 hpf the medium was changed to the same medium containing BDM and the sequential time-lapse images were taken for 3 h every 30 min. The CVP structures did not change significantly for 3 h. Scale bars, 100 μm.
(B) Twenty-four hpf embryos were pre-treated with BDM as in (A), and at 34 hpf the medium was changed to a medium without BDM and the sequential time-lapse images were taken for 3 h every 30 min. Note that subdivisions of CVP accompanied by constriction of vessels were observed (arrows). Scale bars, 100 μm.



Figure 7. Continued

(C) Twenty-four hpf embryos were pre-treated with BDM as in (A), and at 34 hpf the medium was changed to a medium without BDM but containing ONO-8430506, and the sequential time-lapse images were taken for 3 h every 30 min. Note that subdivisions and constriction of CVP were significantly suppressed. Scale bars, 100 μ m.

(D) Ratio of somites with CVP subdivision was quantified by evaluating ten somites (somite a–j in Figures 7A–7C) from each three embryos. All data were expressed as means and SD. p value was calculated by the student's t test (**p < 0.01). See also Videos S21 and S22.

formation. Indeed, actin polymerization downstream of an LPA₄/LPA₆ signal in endothelial cells was recently suggested to stimulate nuclear translocation (activation) of Yap/Taz transcription factors to induce sprouting angiogenesis both *in vivo* and *in vitro* (Yasuda et al., 2019). Thus, it was assumed that the ATX-LPA₆ axis regulates CVP formation through the $G\alpha_{13}$ -RhoA-ROCK pathway. In this study, we showed that knockout or inhibition of each component of an ATX-LPA signal involved in actin stress fiber formation, *i.e.*, ATX, LPA₆, $G\alpha_{13}$, ROCK, and myosin II, caused a similar CVP phenotype in zebrafish (Figures 1, 2, 3, and 4). These results suggest that each factor functions in the same signaling axis in CVP formation. We also analyzed actin cytoskeleton dynamics in CVP using transgenic (Tg) zebrafish line (*Tg(fli1:lifeact-mCherry*)). Inhibition of ATX somehow altered the state of the actin cytoskeleton in CVP, which was revealed by the detection of punctate actin signals (Figures S9 and S10). Interestingly, these signals were abolished by the injection of OMPT, a stable and potent LPA₆ agonist, indicating that the appearance of punctate signals is because of the direct effect of ATX inhibition. Similar punctate signals were observed when amot12 expression was suppressed by MO in zebrafish embryos (Hultin et al., 2014). Amot12 is a factor involved in actin polymerization. Punctate signals of actin were also detected when human umbilical vein endothelial cells (HUVEC) were treated with the ATX inhibitor ONO-8430506 (data not shown). These results support the idea that the punctate signals appear in association with abnormal actin polymerization.

The ATX-LPA₆ axis causes rapid endothelial cell morphological changes

Addition of ATX inhibitor caused rapid (<20 min) changes in the pre-formed CVP, including loss of column structures and obvious vessel fusion (Figure 5). Moreover, injection of OMPT induced dramatic changes in the morphology of endothelial cells leading to vasoconstriction in zebrafish embryos (Figure 6). Of note, the OMPT-induced vasoconstriction occurred very rapidly, i.e., within 20 s (Figure 6). These observations strongly support the idea that rapid actin fiber reorganization induced by an ATX-LPA₆ axis contributed to the formation and maintenance of vessel subdivision. Furthermore, these changes most likely did not involve Yap/Taz transcription factors because control by transcription products generally takes more than 1 h. Thus, in addition to the regulation of the Yap/Taz transcription factor proposed by Yasuda et al. (2019), actin stress fiber formation induced by ATX-LPA₆ signaling induces a morphological change in endothelial cells, which contributes to the formation and maintenance of the CVP in zebrafish (Figure 9).

Zebrafish ATX mutants are not lethal

ATXa/ATXb DKO as well as ATXb KO zebrafish did not show embryonic lethality, unlike ATX KO mice (Figure S2). ATX KO mice showed abnormal formation of blood vessels in the placenta and yolk sac. These vessels are essential for the nutrient supply from the mother to the embryos, and are the main reason why ATX KO is embryonically lethal. On the other hand, in the early stages of zebrafish development, nutrients are supplied to the whole body by free diffusion from the yolk, and early vascular dysplasia is not necessarily lethal.

Based on the DNA sequences of the mutant zebrafish ATX genes, ATX proteins expressed in the ATX mutants are expected to lose their catalytic activity. In fact, we confirmed that plasma lysoPLD activity was almost lost in the KO fish (Figure S3). However, we could not rule out the possibility that truncated ATXb protein with two SMB domains is expressed in the ATXb mutants and suppresses the embryonic lethal phenotype. Precise analysis of mutant ATX proteins will answer the question.

ATX produces unsaturated acyl-LPA species in zebrafish

We measured the circulating LPA acyl-chain species in the plasma from adult zebrafish; the rank order was 18:2-LPA > 22:6-LPA > 20:5-LPA > 20:4-LPA > 18:1-LPA > 16:0-LPA (Figure S13). Administration of ATX inhibitors revealed that these LPA species were mostly produced by ATX (Figure S13). LPA species with unsaturated fatty acids were previously shown to be potent LPA₆ agonists (Yanagida et al., 2009). Previous reports have shown that compared to other LPA receptors, LPA₆ is strongly expressed in some type of endothelial cell such as human umbilical vein endothelial cells (HUVEC) (Yukiura et al., 2015) and primary endothelial cells derived from mouse vessels (Takara et al., 2017). Therefore, we speculate that the LPA







LPA induced contractile force

Figure 8. A proposed model explaining the role of ATX-LPA₆ axis in formation and maintenance of plexus vessels

Plexus vessels are formed from pre-existing vessels both by sprouting and intussusceptive angiogenesis and the following constriction and separation of two pre-formed vessels. The present study proposes that an ATX-LPA₆ axis contributes to vessels' constriction and separation, and also to maintain formed vessels downstream of ATX-LPA₆- $G\alpha_{13}$ signaling.

species produced in the blood are able to act on LPA_6 from the lumen side of the blood vessel, as the initial vessel formation is completed, and blood flow is initiated.

In summary, using zebrafish as a model animal to study the mechanisms of blood vessel formation, we revealed an essential role of an ATX-LPA₆-G α_{13} axis in the formation and maintenance of caudal vein plexus (CVP) as well as the relationship between blood flow and the axis. Our next goal is to see whether an ATX-LPA₆-G α_{13} axis also has a role in blood vessel function in the adult stage.

Limitations of the study

The present study showed that the ATX-LPA₆ axis had a critical role in regulating specific kinds of endothelial cells in caudal vein plexus (CVP) in zebrafish. However, it is still unclear whether the same axis has a role in regulating endothelial cells in other parts and other animals. In addition, it is not clear what the ATX-LPA₆ axis induces cellular events at the cellular level, which requires experiments using endothelial cells in culture.

STAR***METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- **RESOURCE AVAILABILITY**
 - O Lead contact
 - Materials availability
 - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
 - Zebrafish
- METHOD DETAILS
 - O Generation of mutant fish lines
 - O Reagents
 - O Determination of ATX (lysoPLD) activity
 - O Measurement of plasma LPA concentration
 - O Image acquisition, processing, and quantification
 - O Evaluation of CVP constriction
- QUANTIFICATION AND STATISTICAL ANALYSIS





Figure 9. Schematic diagram of the expected function of ATX-LPA₆-Ga₁₃-ROCK axis in CVP formation

LPA produced by ATX activates the LPA₆ receptor on endothelial cells, which induces actin stress fiber formation via $G\alpha_{13}$, RhoA, and ROCK pathway. Actin stress fiber formation is then stimulated and contributes to (1) activation of Yap transcription factor leading to sprouting angiogenesis via β -catenin and Notch signaling pathways, (2) generation of contractile forces on ECs in developing plexus vessels leading to vessel subdivision and separation.

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.isci.2021.103254.

ACKNOWLEDGMENTS

This work was supported by the Leading Advanced Projects for Medical Innovation (LEAP) (Grant Number JP18gm0010004h0002 (to J.A.)) from the Japan Agency for Medical Research and Development (AMED) and KAKENHI (Grant Number JP15H05899 (to J.A.)).

AUTHOR CONTRIBUTIONS

R.O. and J.A. designed the study, interpreted the data. R.O. performed most of the experiments. J.A., R.O. and K.K. wrote the manuscript. R.K. established the LPA₄ mutant zebrafish. A.I. conducted other experiments. S.F. provided technical assistance for experiments evaluating vessel formation in zebrafish. All the authors made the decision to submit the manuscript for publication.

DECLARATION OF INTERESTS

The authors declare no competing interests.



Received: March 26, 2021 Revised: September 6, 2021 Accepted: October 8, 2021 Published: November 19, 2021

REFERENCES

Aikawa, S., Kano, K., Inoue, A., Wang, J., Saigusa, D., Nagamatsu, T., Hirota, Y., Fujii, T., Tsuchiya, S., Taketomi, Y., et al. (2017). Autotaxinlysophosphatidic acid-LPA₃ signaling at the embryo-epithelial boundary controls decidualization pathways. EMBO J. *36*, 2146– 2160.

Apte, R.S., Chen, D.S., and Ferrara, N. (2019). VEGF in signaling and disease: beyond discovery and development. Cell 176, 1248–1264.

Carlson, D.F., Tan, W., Lillico, S.G., Stverakova, D., Proudfoot, C., Christian, M., Voytas, D.F., Long, C.R., Whitelaw, C.B., and Fahrenkrug, S.C. (2012). Efficient TALEN-mediated gene knockout in livestock. Proc. Natl. Acad. Sci. U S A *109*, 17382–17387.

Cermak, T., Doyle, E.L., Christian, M., Wang, L., Zhang, Y., Schmidt, C., Baller, J.A., Somia, N.V., Bogdanove, A.J., and Voytas, D.F. (2011). Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. *39*, e82.

Choi, J., Mouillesseaux, K., Wang, Z., Fiji, H.D., Kinderman, S.S., Otto, G.W., Geisler, R., Kwon, O., and Chen, J.N. (2011). Aplexone targets the HMG-CoA reductase pathway and differentially regulates arteriovenous angiogenesis. Development *138*, 1173–1181.

Estivill-Torrus, G., Llebrez-Zayas, P., Matas-Rico, E., Santin, L., Pedraza, C., De Diego, I., Del Arco, I., Fernandez-Llebrez, P., Chun, J., and De Fonseca, F.R. (2008). Absence of LPA1 signaling results in defective cortical development. Cereb. Cortex 18, 938–950.

Fukushima, N., Ishii, S., Tsujiuchi, T., Kagawa, N., and Katoh, K. (2015). Comparative analyses of lysophosphatidic acid receptor-mediated signaling. Cell Mol. Life Sci. *72*, 2377–2394.

Goetz, J.G., Steed, E., Ferreira, R.R., Roth, S., Ramspacher, C., Boselli, F., Charvin, G., Liebling, M., Wyart, C., Schwab, Y., et al. (2014). Endothelial cilia mediate low flow sensing during zebrafish vascular development. Cell Rep. *6*, 799–808.

Herbert, S.P., Huisken, J., Kim, T.N., Feldman, M.E., Houseman, B.T., Wang, R.A., Shokat, K.M., and Stainier, D.Y. (2009). Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation. Science 326, 294–298.

Hisano, Y., Inoue, A., Taimatsu, K., Ota, S., Ohga, R., Kotani, H., Muraki, M., Aoki, J., and Kawahara, A. (2015). Comprehensive analysis of sphingosine-1-phosphate receptor mutants during zebrafish embryogenesis. Genes Cells 20, 647–658.

Hogan, B.M., and Schulte-Merker, S. (2017). How to plumb a pisces: understanding vascular development and disease using zebrafish embryos. Dev. Cell *42*, 567–583. Hultin, S., Zheng, Y., Mojallal, M., Vertuani, S., Gentili, C., Balland, M., Milloud, R., Belting, H.G., Affolter, M., Helker, C.S., et al. (2014). AmotL2 links VE-cadherin to contractile actin fibres necessary for aortic lumen expansion. Nat. Commun. *5*, 3743.

Inoue, M., Ma, L., Aoki, J., Chun, J., and Ueda, H. (2008). Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain. Mol. Pain 4, 6.

Inoue, M., Rashid, M.H., Fujita, R., Contos, J.J., Chun, J., and Ueda, H. (2004). Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat. Med. 10, 712–718.

Isogai, S., Horiguchi, M., and Weinstein, B.M. (2001). The vascular anatomy of the developing zebrafish: an atlas of embryonic and early larval development. Dev. Biol. *230*, 278–301.

Isogai, S., Lawson, N.D., Torrealday, S., Horiguchi, M., and Weinstein, B.M. (2003). Angiogenic network formation in the developing vertebrate trunk. Development 130, 5281–5290.

Iwaki, Y., Ohhata, A., Nakatani, S., Hisaichi, K., Okabe, Y., Hiramatsu, A., Watanabe, T., Yamamoto, S., Nishiyama, T., Kobayashi, J., et al. (2020). ONO-8430506: a novel autotaxin inhibitor that enhances the antitumor effect of paclitaxel in a breast cancer model. ACS Med. Chem. Lett. 11, 1335–1341.

Jiang, G., Inoue, A., Aoki, J., and Prestwich, G.D. (2013). Phosphorothioate analogs of sn-2 radyl lysophosphatidic acid (LPA): metabolically stabilized LPA receptor agonists. Bioorg. Med. Chem. Lett. 23, 1865–1869.

Jones, E.A., le Noble, F., and Eichmann, A. (2006). What determines blood vessel structure? Genetic prespecification vs. hemodynamics. Physiology 21, 388–395.

Jones, E.A. (2011). The initiation of blood flow and flow induced events in early vascular development. Semin. Cell Dev. Biol. *22*, 1028– 1035.

Kamijo, H., Matsumura, Y., Thumkeo, D., Koike, S., Masu, M., Shimizu, Y., Ishizaki, T., and Narumiya, S. (2011). Impaired vascular remodeling in the yolk sac of embryos deficient in ROCK-I and ROCK-II. Genes Cells *16*, 1012–1021.

Kano, K., Matsumoto, H., Inoue, A., Yukiura, H., Kanai, M., Chun, J., Ishii, S., Shimizu, T., and Aoki, J. (2019). Molecular mechanism of lysophosphatidic acid-induced hypertensive response. Sci. Rep. *9*, 2662.

Kano, K., Matsumoto, H., Kono, N., Kurano, M., Yatomi, Y., and Aoki, J. (2021). Suppressing postcollection lysophosphatidic acid metabolism improves the precision of plasma LPA quantification. J. Lipid Res. *62*, 100029. Karthik, S., Djukic, T., Kim, J.D., Zuber, B., Makanya, A., Odriozola, A., Hlushchuk, R., Filipovic, N., Jin, S.W., and Djonov, V. (2018). Synergistic interaction of sprouting and intussusceptive angiogenesis during zebrafish caudal vein plexus development. Sci. Rep. *8*, 9840.

Kise, R., Okasato, R., Kano, K., Inoue, A., Kawahara, A., and Aoki, J. (2019). Identification and biochemical characterization of a second zebrafish autotaxin gene. J. Biochem. *165*, 269–275.

Koike, S., Keino-Masu, K., Ohto, T., Sugiyama, F., Takahashi, S., and Masu, M. (2009). Autotaxin/ lysophospholipase D-mediated lysophosphatidic acid signaling is required to form distinctive large lysosomes in the visceral endoderm cells of the mouse yolk sac. J. Biol. Chem. 284, 33561–33570.

Kok, F.O., Shin, M., Ni, C.W., Gupta, A., Grosse, A.S., van Impel, A., Kirchmaier, B.C., Peterson-Maduro, J., Kourkoulis, G., Male, I., et al. (2015). Reverse genetic screening reveals poor correlation between morpholino-induced and mutant phenotypes in zebrafish. Dev. Cell 32, 97–108.

Kowalczyk-Zieba, I., Woclawek-Potocka, I., Wasniewski, T., Boruszewska, D., Grycmacher, K., Sinderewicz, E., Staszkiewicz, J., and Wolczynski, S. (2019). LPAR2 and LPAR4 are the main receptors responsible for LPA actions in ovarian endometriotic cysts. Reprod. Sci. 26, 139–150.

Lawson, N.D., and Wolfe, S.A. (2011). Forward and reverse genetic approaches for the analysis of vertebrate development in the zebrafish. Dev. Cell 21, 48–64.

Lee, S.J., Chan, T.H., Chen, T.C., Liao, B.K., Hwang, P.P., and Lee, H. (2008). LPA1 is essential for lymphatic vessel development in zebrafish. FASEB J. 22, 3706–3715.

Lin, K.H., Li, M.W., Chang, Y.C., Lin, Y.N., Ho, Y.H., Weng, W.C., Huang, C.J., Chang, B.E., Yao, C.L., and Lee, H. (2018). Activation of lysophosphatidic acid receptor 3 inhibits megakaryopoiesis in human hematopoietic stem cells and zebrafish. Stem Cells Dev. 27, 216–224.

Luukinen, H., Hammaren, M.M., Vanha-Aho, L.M., and Parikka, M. (2018). Modeling tuberculosis in Mycobacterium marinum infected adult zebrafish. J. Vis. Exp. https://doi.org/10.3791/ 58299.

Mouillesseaux, K.P., Wiley, D.S., Saunders, L.M., Wylie, L.A., Kushner, E.J., Chong, D.C., Citrin, K.M., Barber, A.T., Park, Y., Kim, J.D., et al. (2016). Notch regulates BMP responsiveness and lateral branching in vessel networks via SMAD6. Nat. Commun. 7, 13247.

Nagasawa-Masuda, A., and Terai, K. (2017). Yap/ Taz transcriptional activity is essential for vascular



regression via Ctgf expression and actin polymerization. PLoS One *12*, e0174633.

Nakasaki, T., Tanaka, T., Okudaira, S., Hirosawa, M., Umemoto, E., Otani, K., Jin, S., Bai, Z., Hayasaka, H., Fukui, Y., et al. (2008). Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions. Am. J. Pathol. *173*, 1566–1576.

Nishioka, T., Arima, N., Kano, K., Hama, K., Itai, E., Yukiura, H., Kise, R., Inoue, A., Kim, S.H., Solnica-Krezel, L., et al. (2016). ATX-LPA1 axis contributes to proliferation of chondrocytes by regulating fibronectin assembly leading to proper cartilage formation. Sci. Rep. *6*, 23433.

Ohata, H., Yamada, H., and Momose, K. (2011). Lysophosphatidic acid induces shear stressdependent Ca²⁺ influx in mouse aortic endothelial cells in situ. Exp. Physiol. 96, 468–475.

Ota, S., Hisano, Y., Muraki, M., Hoshijima, K., Dahlem, T.J., Grunwald, D.J., Okada, Y., and Kawahara, A. (2013). Efficient identification of TALEN-mediated genome modifications using heteroduplex mobility assays. Genes Cells 18, 450–458.

Ota, S., Hisano, Y., Ikawa, Y., and Kawahara, A. (2014). Multiple genome modifications by the CRISPR/Cas9 system in zebrafish. Genes Cells *19*, 555–564.

Pearce, J.M. (2006). The craniospinal venous system. Eur. Neurol. *56*, 136–138.

Restrepo, M.S., Aldoss, O., and Ng, B. (2015). Persistent primitive hepatic venous plexus with Scimitar syndrome: description of a case and review of the literature. Cardiol. Young *25*, 1009– 1011.

Ruppel, K.M., Willison, D., Kataoka, H., Wang, A., Zheng, Y.W., Cornelissen, I., Yin, L., Xu, S.M., and Coughlin, S.R. (2005). Essential role for $G\alpha_{13}$ in endothelial cells during embryonic development. Pros. Natl. Acad. Sci. U S A 102, 8281–8286.

Sakai, N., Bain, G., Furuichi, K., Iwata, Y., Nakamura, M., Hara, A., Kitajima, S., Sagara, A., Miyake, T., Toyama, T., et al. (2019). The involvement of autotaxin in renal interstitial fibrosis through regulation of fibroblast functions and induction of vascular leakage. Sci. Rep. 9, 7414.

Savaskan, N.E., Rocha, L., Kotter, M.R., Baer, A., Lubec, G., van Meeteren, L.A., Kishi, Y., Aoki, J., Moolenaar, W.H., Nitsch, R., et al. (2007). Autotaxin (NPP-2) in the brain: cell type-specific expression and regulation during development and after neurotrauma. Cell Mol. Life Sci. 64, 230–243.

Swaney, J.S., Chapman, C., Correa, L.D., Stebbins, K.J., Bundey, R.A., Prodanovich, P.C., Fagan, P., Baccei, C.S., Santini, A.M., Hutchinson, J.H., et al. (2010). A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br. J. Pharmacol. *160*, 1699–1713.

Takara, K., Eino, D., Ando, K., Yasuda, D., Naito, H., Tsukada, Y., Iba, T., Wakabayashi, T., Muramatsu, F., Kidoya, H., et al. (2017). Lysophosphatidic acid receptor 4 activation augments drug delivery in tumors by tightening endothelial cell–cell contact. Cell Rep. 20, 2072– 2086.

Tager, A.M., LaCamera, P., Shea, B.S., Campanella, G.S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B.A., Kim, N.D., et al. (2008). The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat. Med. 14, 45–54.

Tanaka, L.Y., and Laurindo, F.R.M. (2017). Vascular remodeling: a redox-modulated mechanism of vessel caliber regulation. Free Radic. Biol. Med. *109*, 11–21.

Tanaka, M., Okudaira, S., Kishi, Y., Ohkawa, R., Iseki, S., Ota, M., Noji, S., Yatomi, Y., Aoki, J., and Arai, H. (2006). Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J. Biol. Chem. 281, 25822–25830.

Uhl, J.F., Lo Vuolo, M., and Labropoulos, N. (2016). Anatomy of the lymph node venous networks of the groin and their investigation by ultrasonography. Phlebology *31*, 334–343.

Umezu-Goto, M., Kishi, Y., Taira, A., Hama, K., Dohmae, N., Takio, K., Yamori, T., Mills, G.B., Inoue, K., Aoki, J., et al. (2002). Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell. Biol. *158*, 227–233.

van Meeteren, L.A., Ruurs, P., Stortelers, C., Bouwman, P., van Rooijen, M.A., Pradere, J.P., Pettit, T.R., Wakelam, M.J., Saulnier-Blache, J.S., Mummery, C.L., et al. (2006). Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell Biol. 26, 5015–5022. Wakayama, Y., Fukuhara, S., Ando, K., Matsuda, M., and Mochizuki, N. (2015). Cdc42 mediates Bmp-induced sprouting angiogenesis through Fmnl3-driven assembly of endothelial filopodia in zebrafish. Dev. Cell *32*, 109–122.

Wiley, D.M., Kim, J.D., Hao, J., Hong, C.C., Bautch, V.L., and Jin, S.W. (2011). Distinct signalling pathways regulate sprouting angiogenesis from the dorsal aorta and the axial vein. Nat. Cell Biol. *13*, 686–692.

Xie, X., Zhou, T., Wang, Y., Chen, H., Lei, D., Huang, L., Jin, X., Sun, T., Tan, J., Yin, T., et al. (2018). Blood flow regulates zebrafish caudal vein plexus angiogenesis by ERK5-klf2a-nos2b signaling. Curr. Mol. Med. *18*, 3–14.

Yanagida, K., Masago, K., Nakanishi, H., Kihara, Y., Hamano, F., Tajima, Y., Taguchi, R., Shimizu, T., and Ishii, S. (2009). Identidication and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA₆. J. Biol. Chem. 284, 17731– 17741.

Yanagida, K., and Hla, T. (2017). Vascular and immunobiology of the circulatory sphingosine 1phosphate gradient. Annu. Rev. Physiol. 79, 67–91.

Yasuda, D., Kobayashi, D., Akahoshi, N., Ohto-Nakanishi, T., Yoshioka, K., Takuwa, Y., Mizuno, S., Takahashi, S., and Ishii, S. (2019). Lysophosphatidic acid-induced YAP/TAZ activation promotes developmental angiogenesis by repressing Notch ligand Dll4. J. Clin. Invest. *129*, 4332–4349.

Ye, X., Hama, K., Contos, J.J., Anliker, B., Inoue, A., Skinner, M.K., Suzuki, H., Amano, T., Kennedy, G., Arai, H., et al. (2005). LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 435, 104–108.

Yuelling, L.W., Waggener, C.T., Afshari, F.S., Lister, J.A., and Fuss, B. (2012). Autotaxin/ENPP2 regulates oligodendrocyte differentiation in vivo in the developing zebrafish hindbrain. Glia *60*, 1605–1618.

Yukiura, H., Hama, K., Nakanaga, K., Tanaka, M., Asaoka, Y., Okudaira, S., Arima, N., Inoue, A., Hashimoto, T., Arai, H., et al. (2011). Autotaxin regulates vascular development via multiple lysophosphatidic acid (LPA) receptors in zebrafish. J. Biol. Chem. *286*, 43972–43983.

Yukiura, H., Kano, K., Kise, R., Inoue, A., and Aoki, J. (2015). LPP3 localizes LPA6 signalling to noncontact sites in endothelial cells. J. Cell. Sci. *128*, 3871–3877.







STAR*METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Chemicals, peptides, and recombinant proteins		
Tricaine (Ethyl-3-aminobenzoate methanesulfonate)	Sigma Aldrich	Cat#E10521-10G; CAS: 886-86-2
1-Phenyl-2-thioourea (PTU)	Wako	Cat#166-13702
Agarose, low gelling temperature	Sigma Aldrich	Cat#A9414-5G
ONO-8430506	Ono Pharmaceutical Co., Ltd. Iwaki et al. (2020)	CAS: 1354805-08-5
(R)-alkyl-OMPT	Wako	Cat#L-9618
GenomeCraft Cas9	FASMAC	Cat#GE-005-S
Blebbistatin	Sigma Aldrich	Cat#B0506
Rockout	Calbiochem	CAS: 7272-84-6
2,3-Butanedione monoxime (BDM)	Sigma Aldrich	Cat#B0753-25G; CAS: 57-71-6
Critical commercial assays		
mMESSAGE mMACHINE [™] T3 kit	Thermo Fisher Scientific	Cat#AM1348
QIAquick PCR Purification kit	Qiagen	Cat#28106
MEGAshortscript [™] T7 kit	Thermo Fisher Scientific	Cat#AM1354
BCA [™] Protein Assay kit	Thermo Fisher Scientific	Cat#23250
Experimental models: Organisms/strains		
Zebrafish: Tq(fli1:EGFP) ^{y1} : y1Tq, AB line	ZFIN	ZFIN: ZDB-ALT-011017-8
Zebrafish: Tg(fli1:lifeact-mCherry), AB line	Dr. Yuki Wakayama; Wakayama et al. (2015)	N/A
Zebrafish: atxa, AB line	Kise et al. (2019)	N/A
Zebrafish: atxb ^{ro1} , AB line	This paper	N/A
Zebrafish: atxb ^{ro2} , AB line	This paper	N/A
Zebrafish: <i>Ipar4^{rk2}</i> , AB line	This paper	N/A
Zebrafish: <i>Ipar6a^{ro20}</i> , AB line	This paper	N/A
Zebrafish: <i>Ipar6b^{ro23}</i> , AB line	This paper	N/A
Zebrafish: <i>gna13a^{ro8}</i> , AB line	This paper	N/A
Zebrafish: <i>qna13b^{ro10}</i> , AB line	This paper	N/A
Oligonucleotides		
Primer: sgRNA_F: AAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGG ACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC	This paper	N/A
Primer: zATXb_sgRNA_R: TAATACGACTCACTATAGGACTCACGCTCCCAGAATGGTT TTAGAGCTAGAAATAGC	This paper	N/A
Primer: zLPA6a_sgRNA_R: TAATACGACTCACTATAGGTGTTTAGCATCGTCTTCAGT TTTAGAGCTAGAAATAGC	This paper	N/A
Primer: zLPA6b_sgRNA_R: TAATACGACTCACTATAGGTCAACGCTAATGCACGTGGTT TTAGAGCTAGAAATAGC	This paper	N/A

iScience

Article



Continued		
REAGENT or RESOURCE	SOURCE	IDENTIFIER
Primer: zGα ₁₃ a_sgRNA_R: ΤΑΑΤΑCGACTCACTATAGGTACTCGCTGGATGACACTGTTTT AGAGCTAGAAATAGC	This paper	N/A
Primer: $zG\alpha_{13}b_sgRNA_R$: taatacgactcactataggacggggatgacttcgatagtttt agagctagaaatagc	This paper	N/A
Primer: zATXb_F: TCATGTGGAACTCACGCTCCC	This paper	N/A
Primer: zATXb_R: CAGTGTGTAGAGGTTGGGGGAAG	This paper	N/A
Primer: zLPA ₆ a_F: GCTCAATGTGAGCAACGTCA	This paper	N/A
Primer: zLPA ₆ a_R: AGATGTACATGGCGGCAACA	This paper	N/A
Primers for used for detecting mutation in genes except ATXb and LPA_6a, see Table S1 $% \left(\frac{1}{2}\right) =0$	This paper	N/A
Recombinant DNA		
Plasmid: pRClscript-GoldyTALEN	Carlson et al. (2012); Addgene	Cat#42654
Software and algorithms		
TAL Effector Nucleotide Targeter version 2.0	Cornell University	https://tale-nt.cac.cornell.edu
Optimized CRISPR design	MIT, Zhang Lab	N/A
ZEN 2 (blue edition)	ZEISS	N/A
Prism8	GraphPad	N/A

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Junken Aoki (jaoki@mol.f.u-tokyo.ac.jp).

Materials availability

Due to an unfortunate accident, we've lost all zebrafish lines. Thus, zebrafish lines generated in this study are not available.

Data and code availability

- All data reported in this paper will be shared by the lead contact upon request.
- This paper does not report original code.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Zebrafish

Fishes used in this study were AB background transgenic fish, $Tg(fli1:EGFP)^{y1}$ and Tg(fli1:lifeact-mCherry); and AB background mutant lines, $atxa^{rk1}$, $atxb^{ro1}$, $atxb^{ro2}$, $lpar4^{rk2}$, $lpar6a^{ro20}$, $lpar6b^{ro23}$, $gna13a^{ro8}$ and $gna13b^{ro10}$. $Tg(fli1:EGFP)^{y1}$ were obtained from the Zebrafish International Resource Center (University of Oregon, Eugene, OR). Tg(fli1:lifeact-mCherry) was established in Wakayama et al. (2015). Fishes were maintained at 27–28°C under a controlled 13.5-h light/10.5-h dark cycle. Embryos were obtained from natural spawning and kept in E2 embryo medium (15.0 mM NaCl, 0.5 mM KCl, 1.0 mM MgSO₄, 0.15 mM KH₂PO₄, 0.05 mM Na₂HPO₄, 1.0 mM CaCl₂, 0.7 mM NaHCO₃) at 27–28°C. For vessel observation, embryos





were treated with 0.003% 1-phenyl-2-thiourea (Sigma) from 24 hpf. Adult fishes used for plasma preparation were male and 3 to 12 months old. All animal experiments were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee at Tohoku University and Animal Committees of the University of Tokyo following the Standards Relating to the Care and Management of Experimental Animals in Japan.

METHOD DETAILS

Generation of mutant fish lines

An *Lpar4* mutant was prepared using TALEN-mediated mutagenesis, as described previously. TALEN constructs targeting *lpar4* were designed using online software (TAL Effector Nucleotide Targeter version 2.0, https://tale-nt.cac.cornell.edu). The left and right arms of TALEN targeting sequences were 5'-GGTACG CACTCGTGCACT-3' and 5'-AGGGTTCTTGCAAGCCTCTCC-3', respectively. A targeting construct was generated by the Golden Gate assembly method as described previously (Cermak et al., 2011). Module, array, last repeat and backbone plasmids were assembled by Bral digestion and DNA ligation. The destination vector pRClscript-GoldyTALEN (Carlson et al., 2012) was obtained from Addgene (Watertown, MA). The vector was linearized by Sacl digestion, and mRNA was synthesized using mMESSAGE mMACHINE T3 kit (Thermo Fisher Scientific) and purified by lithium chloride precipitation. Forward- and reverse-TALEN mRNAs (400 pg each) were injected together into one-cell-stage embryos.

Zebrafish mutants of *atxb*, *Ipar6a*, *Ipar6b*, *gna13a*, and *gna13b* were generated using CRISPR as previously described (Ota et al., 2014) with minor modifications. The sgRNAs were designed using Optimized CRISPR design (MIT, Zhang Lab). Template DNAs for the synthesis of sgRNAs were prepared by PCR amplification using oligonucleotide primers (Table S1). The PCR products were purified using a QIAquick PCR Purification kit (Qiagen). sgRNAs were transcribed using MEGAshortscriptTM T7 kit (Thermo Fisher Scientific) and purified by phenol-chloroform extraction and EtOH precipitation. sgRNAs were mixed with Cas9 protein (FASMAC) and injected into 1–2 cell stage embryos. Double KO mutants of *Ipar6a/Ipar6b* and *gna13a/gna13b* were obtained by injecting two sgRNAs. *atxa/atxb* double and *Ipar4/Ipar6a/Ipar6b* triple mutants were obtained by injecting into *atxa^{-/-}* and *Ipar4^{-/-}* embryos, respectively. Each mutation was confirmed by a heteroduplex mobility assay, as previously described (Ota et al., 2013). DNA fragments which include the target site were amplified using primers listed in Table S1 and electrophoresed on 15% polyacrylamide gels. Mutagenesis was evaluated by the appearance of bands derived from heteroduplexes.

Reagents

ATX inhibitor, ONO-8430506 (lwaki et al., 2020) was kindly provided from Ono Pharmaceutical Co., Ltd. ONO-8430506 was dissolved in DMSO and used at ten μ M (*in vitro* experiment) or 100 μ M (*in vivo* experiment). Blebbistatin was purchased from SIGMA, dissolved in DMSO, and used at 6.25 μ M. OMPT ((*R*)-alkyl-OMPT) was dissolved in 0.1%BSA/PBS and was used at 500 or 1000 μ M for *in vivo* injection experiments. Rockout was purchased from Calbiochem, dissolved in DMSO, and used at 50 μ M.

Determination of ATX (lysoPLD) activity

LysoPLD assay was performed as described previously (Kise et al., 2019), except for the incubation time with substrate. For blood collection, adult zebrafish were anesthetized by Tricaine (SIGMA) and cut between the anal fin and the caudal fin with a surgical razor blade. The exuded blood was collected into a tube filled with PBS (100 μ l) containing 5U/mL heparin by immersing the fins in the PBS. The blood was centrifuged at 500 × g for 10 minutes, and the supernatant was used as a diluted plasma. Protein concentration was determined by BCA assay (Thermo Fisher Scientific). The diluted plasma (10 μ l) was added to lysoPLD assay buffer (total volume 60 μ l) containing 14:0 (myristoyl)-LPC (2 mM) and incubated at 37°C. After 48 hours, free choline concentration in the tube was determined by choline colorimetrical assay (Umezu-Goto et al., 2002). The liberated choline was detected by an enzymatic photometric method using choline oxidase, horseradish peroxidase (Toyobo), and TOOS reagent as a hydrogen donor.

Measurement of plasma LPA concentration

Intraperitoneal injection of ATX inhibitor into adult zebrafish was performed as described previously (Luukinen et al., 2018). An ATX inhibitor ONO-8430506 in DMSO (100 mM \times 7 μ L) and vehicle control (DMSO, 7 μ L) was injected using 30 G needle. Blood was collected 40 minutes after the administration. For blood collection, adult zebrafish were anesthetized by Tricaine (SIGMA) and cut between the anal fin and the





caudal fin with a surgical razor blade. 1 μ L of exuded blood was taken from one adult fish and totally 10 μ L of blood was collected in 20 μ l of PBS containing 5U/mL heparin from 10 adult fishes. For blood collection, we used P10 pipettor with pipette tips, which was coated with heparin in advance. The diluted blood was centrifuged at 1500 × g for 10 minutes at 4°C, and the supernatant was used as diluted plasma. Measurement of LPA in the diluted plasma was performed as recently described (Kano et al., 2021). The methanol extract containing internal standard (100 μ M 17:0 LPA) was subjected to LC-MS/MS.

Image acquisition, processing, and quantification

Embryos were embedded in a drop of low melting point agarose (1%) containing 0.016% Tricaine and 0.003% 1-phenyl-2-thiourea. Images of embryos were captured with LSM 800 confocal laser-scanning microscope (Carl Zeiss) equipped with Plan-Apochromat $10 \times /0.45$ M27 or Plan-Apochromat $20 \times /0.8$ M27 objective. In this study, we called the ten somites from the end of the yolk extension as somites a-j, respectively, and area of columns and vessels were quantified with Zen 2 (blue edition) software. Cross-sectional images were taken at the center of each somite. For confocal time-lapse imaging, images were collected every 20 or 30 minutes for 4–6 hours.

Evaluation of CVP constriction

Embryos fixed in soft agar were injected with OMPT (500 or 1,000 μ M) dissolved in 0.1% BSA/PBS containing 0.2% Evans blue in a total volume of 1 nl using a micro-injector in the vicinity of the heart. Time-lapse images were promptly acquired by confocal microscopy every 5 or 20 seconds for 5 minutes. For evaluation of vasoconstriction, changes in the long axis of the elliptical vessel lumen of the CVP were assessed for 5 minutes, and the rate of constriction was calculated by dividing the value at 5 minutes by the value at time 0.

QUANTIFICATION AND STATISTICAL ANALYSIS

All statistical analyses were carried out using Prism software (GraphPad). Statistical significance between two groups is evaluated by Student's t test, and p < 0.05 was considered to be significant. All data were expressed as means \pm SD using Prism software (GraphPad). Zen 2 (blue edition) software was used for image quantification of vascular images. Number of samples are included in figure legends.